NanoViricides is trading 5.2% up at $1.10 after announcing on September 15, 2026, that its Phase II trial of NV-387 oral gummies for Ebola is scheduled to begin next week in the Democratic Republic of Congo.
- Evaluates treatment against Bundibugyo ebolavirus at an Ebola Treatment Center in Ituri province.
- Company-specific catalyst appears to outweigh weaker biotech-sector sentiment; no additional major announcement identified.
- Move is based on live early-session trading; volume data unavailable.